


Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please amend claims 1 and 7 to 10 as indicated.


Please cancel claim 2 without prejudice or disclaimer.

Claim 1. (currently amended): A compound of formula (I):



wherein:

one of R^1 and R^2 is a group (IA):



and the other of R^1 and R^2 is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocycloxy and heterocycloxy; wherein this R^1 or R^2 is optionally substituted on carbon by one or more groups selected from R^5 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4} alkyl; **Ring A** is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R^6 ;

one of **R**³ and **R**⁴ is hydrogen and the other is selected from hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein **R**³ and **R**⁴ are independently optionally substituted on carbon by one or more groups selected from **R**⁷; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl;

R⁶ is selected from halo, carboxy and C₁₋₄alkyl;

R⁵ and **R**⁷ are independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, *N*-(C₁₋₄alkyl)amino, *N,N*-(C₁₋₄alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclylidenyl; wherein **R**⁵ and **R**⁷ are independently optionally substituted on carbon by one or more **R**⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C₁₋₄alkyl; and

R⁸ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino; or a salt, solvate or pro-drug thereof.

Claim 2. (cancelled).

Claim 3. (previously presented): A compound according to Claim 2 wherein Ring A in the group (IA) is substituted by carboxy and the C₁₋₄alkoxy group is substituted on carbon by one or more groups selected from **R**⁵.

Claim 4. (original): A compound according to Claim 3 wherein **R**⁵ is selected from carbocyclyl optionally substituted by one or more **R**⁸.

Claim 5. (previously presented): A compound according to Claim 1 wherein one of **R**³ and **R**⁴ is hydrogen and the other is C₁₋₄alkyl.

Claim 6. (original): A compound according to Claim 1 selected from:


2-(2-Chlorobenzoyloxy)-4-[*N*-5-carboxythiazol-2-yl]carbamoyl]-6-methylquinoline;
2-(2-Chlorobenzoyloxy)-4-[*N*-5-carboxythiazol-2-yl]carbamoyl]-quinoline;
2-(2-Chlorobenzoyloxy)-4-[*N*-5-carboxypyrid-2-yl]carbamoyl]-6-methylquinoline;
2-(2-Chlorobenzoyloxy)-4-[*N*-5-carboxypyrid-2-yl]carbamoyl]-quinoline;
2-[*N*-5-carboxypyrid-2-yl]carbamoyl]-4-(2-methylbenzoyloxy)-quinoline; and
2-(1-methylpropoxy)-4-[*N*-(5-carboxythiazol-2-yl)carbamoyl]-quinoline;

or a salt, solvate or pro-drug thereof.

Claim 7. (currently amended): A pharmaceutical composition comprising a compound according to any one of Claims 1 and 3 to 6, or a salt, pro-drug or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.


Claim 8. (currently amended): A method of treating diabetes and/or obesity by a disease mediated through glucokinase, comprising administering an effective amount of a compound according to Claim 1 or a salt, solvate or pro-drug thereof, to a mammal in need of such treatment ~~any one of Claims 1 to 6.~~

Claim 9. (currently amended): A process for preparing a compound of formula (I):



wherein:

one of **R¹** and **R²** is a group (IA):



and the other of R^1 and R^2 is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein this R^1 or R^2 is optionally substituted on carbon by one or more groups selected from R^5 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4} alkyl;

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R^6 ;

one of R^3 and R^4 is hydrogen and the other is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R^3 and R^4 are independently optionally substituted on carbon by one or more groups selected from R^7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4} alkyl;



R^6 is selected from halo, carboxy and C_{1-4} alkyl;

R^5 and R^7 are independently selected from halo, C_{1-4} alkyl, C_{1-4} alkoxy, N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclidenyl; wherein R^5 and R^7 are independently optionally substituted on carbon by one or more R^8 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4} alkyl; and


R^8 is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N -methyl- N -ethylamino;

or a salt, solvate or pro-drug thereof, which process comprises:

Process 1): reacting an acid of formula (IIa) or (IIb):





or an activated derivative thereof; with a compound of formula (III)



or

Process 2): for compounds of formula (I) wherein R⁶ is carboxy; deprotecting a compound of formula (IIIa) or (IIIb):



wherein $R^x C(O)O-$ is an ester group;

and thereafter if necessary or desirable:


i) converting a compound of the formula (I) into another compound of the formula (I);

and/or

ii) removing any protecting groups; and/or

iii) forming a salt, solvate or pro-drug thereof.

Claim 10. (currently amended): A compound of formula (IIIa) or a compound of formula (IIIb):



wherein $R^x C(O)O-$ is an ester group;

R^1 and R^2 is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein this R^1 or R^2 is optionally substituted on carbon by one or more groups selected from R^5 ; and wherein if said heterocyclyl contains an $-NH-$ moiety that nitrogen is optionally substituted by C_{1-4} alkyl;

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R^6 ;

one of R^3 and R^4 is hydrogen and the other is selected from hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R^3 and R^4 are

independently optionally substituted on carbon by one or more groups selected from R^7 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4} alkyl;

R^6 is selected from halo, carboxy and C_{1-4} alkyl;

R^5 and R^7 are independently selected from halo, C_{1-4} alkyl, C_{1-4} alkoxy,

N -(C_{1-4} alkyl)amino, N,N -(C_{1-4} alkyl)₂amino, carbocyclyl, heterocyclyl, carbocycloxy,

heterocycloxy and carbocyclidenyl; wherein R^5 and R^7 are independently optionally substituted on carbon by one or more R^8 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4} alkyl; and

R^8 is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and N -methyl- N -ethylamino.